163 related articles for article (PubMed ID: 1683403)
1. Oral cabergoline. Single-dose inhibition of puerperal lactation.
Caballero-Gordo A; Lopez-Nazareno N; Calderay M; Caballero JL; Mancheño E; Sghedoni D
J Reprod Med; 1991 Oct; 36(10):717-21. PubMed ID: 1683403
[TBL] [Abstract][Full Text] [Related]
2. Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.
Melis GB; Mais V; Paoletti AM; Beneventi F; Gambacciani M; Fioretti P
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):311-4. PubMed ID: 3279351
[TBL] [Abstract][Full Text] [Related]
3. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
BMJ; 1991 Jun; 302(6789):1367-71. PubMed ID: 1676318
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery.
Giorda G; de Vincentiis S; Motta T; Casazza S; Fadin M; D'Alberton A
Gynecol Obstet Invest; 1991; 31(2):93-6. PubMed ID: 2037265
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
[TBL] [Abstract][Full Text] [Related]
6. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
8. Effect of an injectable cabergoline formulation on serum prolactin (PRL) and milk secretion in early postpartum Beagle bitches.
Romagnoli S; Milani C; Perin S; Ballabio R; Stelletta C; Mollo A; Gelli D
Reprod Domest Anim; 2009 Jul; 44 Suppl 2():148-51. PubMed ID: 19754555
[TBL] [Abstract][Full Text] [Related]
9. [The effect of several sexual steroids, 2-bromo-ergokryptin and lisurid-hydrogenmaleate an the postpartum concentration of serum prolactin and lactation (author's transl)].
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; Michel E; Nevinny-Stickel J
Geburtshilfe Frauenheilkd; 1977 Jun; 37(6):500-8. PubMed ID: 328335
[TBL] [Abstract][Full Text] [Related]
10. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline: a new drug for the treatment of hyperprolactinaemia.
Ferrari C; Piscitelli G; Crosignani PG
Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955
[TBL] [Abstract][Full Text] [Related]
12. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
13. Suppression of puerperal lactation by metergoline.
Crosignani PG; Lombroso GC; Caccamo A; Reschini E; Peracchi M
Obstet Gynecol; 1978 Jan; 51(1):113-5. PubMed ID: 619329
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lactation by a long-acting bromocriptine.
Peters F; Del Pozo E; Conti A; Breckwoldt M
Obstet Gynecol; 1986 Jan; 67(1):82-5. PubMed ID: 3940343
[TBL] [Abstract][Full Text] [Related]
15. Control of red fox (Vulpes vulpes) fertility with cabergoline: dose response and timing of intervention.
Marks CA; Jalkanen L; Savolainen R; Short RV
Reproduction; 2001 Jul; 122(1):147-54. PubMed ID: 11425339
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
[TBL] [Abstract][Full Text] [Related]
17. Effect of prostaglandin E2 on puerperal breast discomfort and prolactin secretion.
Tulandi T; Gelfand MM; Maiolo L
J Reprod Med; 1985 Mar; 30(3):176-8. PubMed ID: 3858547
[TBL] [Abstract][Full Text] [Related]
18. [Dostinex - the most effective medicine for inhibition of postpartal lactation].
Bozhinova S; Porozhanova V; Penkov V
Akush Ginekol (Sofiia); 2001; 40(4):11-4. PubMed ID: 11803861
[TBL] [Abstract][Full Text] [Related]
19. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Sghedoni D; Fioretti P
Fertil Steril; 1989 Sep; 52(3):412-5. PubMed ID: 2570719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
